Weekly Research Analysts’ Ratings Updates for AxoGen (AXGN)

Several analysts have recently updated their ratings and price targets for AxoGen (NASDAQ: AXGN):

• 10/30/2025 – AxoGen was given a new $34.00 price target on by analysts at JMP Securities.
• 10/30/2025 – AxoGen had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 10/30/2025 – AxoGen had its price target raised by analysts at HC Wainwright from $25.00 to $26.00. They now have a “buy” rating on the stock.
• 10/30/2025 – AxoGen had its price target raised by analysts at Raymond James Financial, Inc. from $20.00 to $27.00. They now have an “outperform” rating on the stock.
• 10/30/2025 – AxoGen had its price target raised by analysts at Canaccord Genuity Group Inc. from $24.00 to $27.00. They now have a “buy” rating on the stock.
• 10/30/2025 – AxoGen had its price target raised by analysts at Citizens Jmp from $26.00 to $34.00. They now have a “market outperform” rating on the stock.
• 10/29/2025 – AxoGen had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc..
• 10/8/2025 – AxoGen had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/30/2025 – AxoGen is now covered by analysts at HC Wainwright. They set a “buy” rating and a $25.00 price target on the stock.
• 9/30/2025 – AxoGen is now covered by analysts at HC Wainwright. They set a “buy” rating and a $25.00 price target on the stock.
• 9/27/2025 – AxoGen had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In other AxoGen news, Director William P. Mr. Burke sold 18,248 shares of AxoGen stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $23.00, for a total value of $419,704.00. Following the completion of the transaction, the director directly owned 100 shares of the company’s stock, valued at approximately $2,300. The trade was a 99.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have sold 94,004 shares of company stock worth $1,888,752. 2.78% of the stock is currently owned by company insiders.

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.